市場調査レポート

商品コード

1601615

微小残存病変検査市場規模、シェア、予測、動向分析：提供別、技術別（PCR、フローサイトメトリー、NGS）、用途別（リンパ腫、白血病、多発性骨髄腫、固形腫瘍）、検体タイプ別（血液、骨髄） - 2031年までの世界予測

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) - Global Forecast to 2031

出版日: 2024年11月27日
発行: Meticulous Research
ページ情報: 英文 265 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,175 601,450円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,875 846,352円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global Site License)

USD 7,875 1,134,472円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

微小残存病変（MRD）検査の市場規模、シェア、予測、動向分析：提供サービス、技術（PCR、フローサイトメトリー、NGS）、用途（リンパ腫、白血病、多発性骨髄腫、固形腫瘍）、サンプル（血液、骨髄）別-2031年までの世界予測

この調査レポートは微小残存病変検査市場の規模、シェア、予測、動向分析：提供、技術（PCR、フローサイトメトリー、NGS）、用途（リンパ腫、白血病、多発性骨髄腫、固形がん）、サンプル（血液、骨髄）別-2031年までの世界予測」と題する新しい市場調査報告書です。微小残存病変検査市場は2031年までに44億5,000万米ドルに達すると予測され、予測期間2024-2031年のCAGRは14.6%です。

微小残存病変（MRD）検査は、がん罹患患者にとって極めて重要です。MRD検査は、治療を受けたがん患者が再発やがんの再発のリスクがあるかどうかを早期に洞察します。早期の情報は、医師ががんの種類や再発率に応じて治療を決定するのに役立ち、患者の転帰の改善や生活の質の向上につながる可能性があります。さらに、MRD検査は、がん治療法の開発に注力する製薬会社やバイオ製薬会社による臨床試験でますます使用されるようになっています。これらは、MRD検査の世界の採用を促進する主な要因の一部です。

微小残存病変検査市場の成長は、がんの罹患率の増加、血液学的悪性腫瘍におけるMRDの適用の増加、一部のがんの高い再発率、MRD検査への投資と資金の増加によってもたらされます。さらに、新興経済国、腫瘍学分野における個別化治療と標的療法の採用の増加、固形腫瘍の症例におけるMRD検査の使用の増加は、市場成長の機会を生み出すと予想されます。

がん領域における個別化治療と標的療法の採用増加

研究者が腫瘍特有の遺伝子プロファイルを特定できるようになったことで、MRD検査は個別化腫瘍学医療で支持を集めています。患者に残存するがん細胞を特定することで、医師は治療の強度を決定したり、治療に対する個人の反応に基づいて治療を調整したりすることができます。MRD検査は、治療効果を向上させ、患者管理をより正確にするための個別化医療と密接に関係しています。

MRD検査を臨床経路に組み込むことで、標的治療の妥当性を確認することができます。特定の遺伝子変異を標的とする新薬が開発される中、MRD検査は治療効果に関する貴重な洞察を提供することができます。例えば、2023年に米国FDAは希少疾患に対する16の個別化治療を承認したが、そのうち7つはがんに対するものでした。標的治療とMRD検査を組み合わせることで、早期介入戦略を促進し、再発を予防し、患者の長期転帰を改善できる可能性があります。このように、がん領域における個別化治療と標的治療へのシフトは、MRD（Minimal Residual Disease）検査市場で事業を展開するプレーヤーに成長機会をもたらすと期待されています。

微小残存病変検査市場将来展望

本レポートで調査した製品のうち、2024年にはアッセイ&試薬セグメントが微小残存病変検査市場の最大シェア76.7%を占めると予想されます。アッセイ＆試薬の反復使用、新しいMRD検査の出現につながる腫瘍学分野の研究開発の増加、微小残存病変検査のための新しいアッセイの導入に対する市場プレイヤーの注力、臨床試験におけるMRD検査の採用の高まりなどが、このセグメントの大きな市場シェアに寄与しています。

本レポートで調査した技術のうち、2024年にはフローサイトメンテーション分野が微小残存病変検査市場で42.7%の最大シェアを占めると予想されます。同分野の市場シェアが大きいのは、サンプル中のがん細胞の数と種類に関する定量データをリアルタイムで提供できること、フローサイトメーターが広く普及していること、次世代シーケンシング（NGS）などのより高度な技術と比較してフローサイトメトリーの消耗品のコストが比較的低いことなどによる。

本レポートで調査したアプリケーションのうち、2024年には血液がん分野が微小残存病変検査市場で大きなシェアを占めると予想されます。このセグメントの大きなシェアは、血液がんの発生率の増加、新しい診断技術の登場、精密腫瘍学への注目の高まり、血液がんのMRD検査への投資の高さ、血液がん用のMRD検査ソリューションの幅広い利用可能性などに起因しています。

本レポートで調査したサンプルタイプのうち、2024年には血液セグメントが微小残存病変検査市場で最大のシェアを占めると予想されます。このセグメントは、がん罹患率の増加、血液サンプルを採取するための手順が非侵襲的であること、定期的な血液ベースのMRDモニタリングの場合に患者のコンプライアンスが向上することなどにより、大きな市場シェアを占めています。

本レポートで調査した顧客タイプのうち、2024年には製薬・バイオ製薬企業セグメントが微小残存病変検査市場で最大のシェアを占めると予想されます。このセグメントの市場シェアが大きいのは、がん治療薬の臨床試験におけるMRD検査の採用率が高いこと、がん治療薬の研究開発への投資が多いこと、医薬品臨床試験におけるMRD検査を促進するための規制当局による支援イニシアチブがあることによる。

本レポートで調査した地域のうち、2024年にはアジア太平洋地域が予測期間中に最も高いCAGRを記録すると推定されます。アジア太平洋地域は、ヘルスケアインフラの改善により、ヘルスケア製品メーカーやサービスプロバイダーにとってますます活発な市場となっています。アジア太平洋地域の人口増加は、同地域のヘルスケア部門を牽引する重要な要因です。この成長により、MRD検査ソリューションの開発に民間および公的機関からの投資が集まっています。がん罹患率の上昇、ヘルスケアインフラの改善、個別化治療への注目の高まり、がん検診イニシアチブの増加、がん研究への資金提供の可能性が、アジア太平洋地域の市場成長を促進しています。

本レポートで調査している主な企業は、Illumina, Inc.（米国）、Qiagen N.V.（オランダ）、PerkinElmer, Inc.（米国）、F. Hoffmann-La Roche Ltd.（スイス）、Thermo Fisher Ltd.（スイス）です。（米国）、Thermo Fisher Scientific, Inc.（スイス）、Natera Inc.（米国）、Bio-Rad Laboratories, Inc.（米国）、Adaptive Biotechnologies Corporation（米国）、シスメックス株式会社（日本）、Integrated DNA Technologies, Inc.（米国）、Twist Bioscience Corporation（米国）、Invivoscribe Inc.（米国）。

市場概要
市場成長に影響を与える要因
- 促進要因
  - がん罹患率の増加
  - MRD検査および調査への投資および資金調達の増加
- 抑制要因
  - 微小残存病変検査のコスト高
- 機会
  - がん領域における個別化治療と標的治療の採用の増加
  - 固形がんにおけるMRD検査の使用事例の増加
- 課題
  - 偽陽性/陰性の可能性
- 動向
  - デジタルPCRの出現
  - MRD検査における質量分析の利用
  - 微小残存病変検査へのシングルセル・マルチオミクスと人工知能の統合
- 要因分析
規制分析
- 北米
  - 米国
  - カナダ
- 欧州
- アジア太平洋
  - 中国
  - 日本
  - インド
- ラテンアメリカ
- 中東
ポーターのファイブフォース分析
技術進化のロードマップ

第5章微小残存病変検査市場の評価-提供別

概要
アッセイ＆試薬
検査機器
ソフトウェア＆サービス

第6章微小残存病変検査市場の評価-技術別

概要
フローサイトメトリー
ポリメラーゼ連鎖反応
次世代シーケンサー
その他の技術

第7章微小残存病変検査市場の評価-用途別

概要
血液がん
- リンパ腫
- 白血病
  - 急性リンパ芽球性白血病（ALL）
  - 慢性リンパ性白血病（CLL）
  - その他の白血病
- 多発性骨髄腫
- その他の血液がん
固形腫瘍

第8章微小残存病変検査市場の評価-検体タイプ別

概要
血液
骨髄
その他のサンプルタイプ

第9章微小残存病変検査市場の評価-顧客タイプ別

概要
製薬・バイオ製薬企業
病院
診断研究所
学術・研究機関/研究機関

第10章微小残存病変検査市場の評価-地域別

概要
北米
- 米国
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- スイス
- オランダ
- その他欧州
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- メキシコ
- その他ラテンアメリカ
中東・アフリカ

第11章競合情勢

概要
主要成長戦略
競合ベンチマーキング
競合ダッシュボード
- 業界リーダー
- 市場差別化要因
- 先行企業
- 新興企業
市場シェア分析（2023年）
- Natera Inc.（U.S.）
- Bio-Rad Laboratories, Inc.（U.S.）
- F. Hoffmann-La Roche Ltd.（Switzerland）
- Adaptive Biotechnologies Corporation（U.S.）

第12章企業プロファイル

Natera Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Adaptive Biotechnologies Corporation
Illumina, Inc.
Thermo Fisher Scientific, Inc.
Qiagen N.V.
Integrated DNA Technologies, Inc.（U.S.）（A Subsidiary of Danaher Corporation[U.S.]）
Twist Bioscience Corporation
Sysmex Corporation
Invivoscribe, Inc.

第13章付録

図表

LIST OF TABLES

Table 1 Global Estimated Number of New Cancer Cases, By Type, 2020 Vs. 2030
Table 2 Cancer Recurrence Rates, By Cancer Type
Table 3 FDA-Approved Personalized Therapies for Cancer, 2019-2023
Table 4 Regulatory Authorities Governing IVD, Flow Cytometry, PCR, and NGS Products, By Country/Region
Table 5 Global Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 6 Key Market Players' Assay & Reagent Offerings
Table 7 Global Minimal Residual Disease Testing Assays & Reagents Market, By Country/Region, 2022-2031 (USD Million)
Table 8 Key Market Players' Instrument Offerings
Table 9 Global Minimal Residual Disease Testing Instruments Market, By Country/Region, 2022-2031 (USD Million)
Table 10 Key Market Players' Software Offerings
Table 11 Global Minimal Residual Disease Testing Software & Services Market, By Country/Region, 2022-2031 (USD Million)
Table 12 MRD Testing Technologies: Overview
Table 13 Global Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 14 Global Flow Cytometry-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 15 Global PCR-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 16 Global NGS-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 17 Global Other Technologies-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 18 Global Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million) 90
Table 19 Global Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 20 Global Minimal Residual Disease Testing Market for Blood Cancers, By Country/Region, 2022-2031 (USD Million) 92
Table 21 Estimated Number of New Lymphoma Cases, By Region, 2022 Vs. 2025 Vs. 2030 (Thousand)
Table 22 Survival Rates for Diffuse Large B-Cell Lymphoma, By Seer Stage (%)
Table 23 Survival Rates for Follicular Lymphoma, By Seer Stage (%)
Table 24 Reoccurrence Rates In Lymphoma-Affected Patients, By Condition (%)
Table 25 Global Minimal Residual Disease Testing Market for Lymphoma, By Country/Region, 2022-2031 (USD Million)
Table 26 Global Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 27 Global Minimal Residual Disease Testing Market for Leukemia, By Country/Region, 2022-2031 (USD Million)
Table 28 Global Minimal Residual Disease Testing Market for Acute Lymphoblastic Leukemia, By Country/Region, 2022-2031 (USD Million)
Table 29 Global Minimal Residual Disease Testing Market for Chronic Lymphocytic Leukemia, By Country/Region, 2022-2031 (USD Million)
Table 30 Global Minimal Residual Disease Testing Market for Other Leukemias, By Country/Region, 2022-2031 (USD Million)
Table 31 Global Minimal Residual Disease Testing Market for Multiple Myeloma, By Country/Region, 2022-2031 (USD Million)
Table 32 Types of Myelodysplastic Syndromes
Table 33 Types of Myeloproliferative Neoplasms
Table 34 Global Minimal Residual Disease Testing Market for Other Blood Cancers, By Country/Region, 2022-2031 (USD Million)
Table 35 Global Estimated Number of New Cancer Cases, By Type, 2020 Vs. 2030
Table 36 Global Minimal Residual Disease Testing Market for Solid Tumors, By Country/Region, 2022-2031 (USD Million)
Table 37 Global Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 38 Global Blood-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 39 Global Bone Marrow-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 40 Global Other Samples-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 41 Global Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 42 Global Minimal Residual Disease Testing Market for Pharmaceutical & Biopharmaceutical Companies, By Country/Region, 2022-2031 (USD Million)
Table 43 Global Minimal Residual Disease Testing Market for Hospitals, By Country/Region, 2022-2031 (USD Million)
Table 44 Global Minimal Residual Disease Testing Market for Diagnostic Laboratories, By Country/Region, 2022-2031 (USD Million)
Table 45 Global Minimal Residual Disease Testing Market for Academic & Research Organizations/Institutions, By Country/Region, 2022-2031 (USD Million)
Table 46 Global Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 47 North America: Minimal Residual Disease Testing Market, By Country, 2022-2031 (USD Million)
Table 48 North America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 49 North America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 50 North America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 51 North America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 52 North America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 53 North America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 54 North America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 55 U.S.: Estimated Number of New Cancer Cases By Type & State, 2024
Table 56 U.S.: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 57 U.S.: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 58 U.S.: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 59 U.S.: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 60 U.S.: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 61 U.S.: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 62 U.S.: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 63 Canada: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 64 Canada: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 65 Canada: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 66 Canada: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 67 Canada: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 68 Canada: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 69 Canada: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 70 Europe: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 71 Europe: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 72 Europe: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 73 Europe: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 74 Europe: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 75 Europe: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 76 Europe: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 77 Europe: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 78 Germany: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 79 Germany: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 80 Germany: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 81 Germany: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 82 Germany: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 83 Germany: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 84 Germany: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 85 U.K.: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 86 U.K.: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 87 U.K.: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 88 U.K.: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 89 U.K.: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 90 U.K.: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 91 U.K.: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 92 France: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 93 France: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 94 France: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 95 France: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 96 France: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 97 France: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 98 France: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 99 Italy: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 100 Italy: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 101 Italy: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 102 Italy: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 103 Italy: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 104 Italy: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 105 Italy: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 106 Spain: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 107 Spain: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 108 Spain: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 109 Spain: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 110 Spain: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 111 Spain: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 112 Spain: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 113 Switzerland: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 114 Switzerland: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 115 Switzerland: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 116 Switzerland: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 117 Switzerland: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 118 Switzerland: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 119 Switzerland: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 120 Netherlands: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 121 Netherlands: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 122 Netherlands: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 123 Netherlands: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 124 Netherlands: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 125 Netherlands: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 126 Netherlands: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 127 Rest of Europe: Number of New Cancer Cases, By Country, 2022 Vs. 2030
Table 128 Rest of Europe: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 129 Rest of Europe: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 130 Rest of Europe: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 131 Rest of Europe: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 132 Rest of Europe: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 133 Rest of Europe: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 134 Rest of Europe: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 135 Asia-Pacific: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 136 Asia-Pacific: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 137 Asia-Pacific: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 138 Asia-Pacific: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 139 Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 140 Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 141 Asia-Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 142 Asia-Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 143 China: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 144 China: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 145 China: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 146 China: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 147 China: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 148 China: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 149 China: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 150 Japan: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 151 Japan: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 152 Japan: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 153 Japan: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 154 Japan: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 155 Japan: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 156 Japan: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 157 India: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 158 India: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 159 India: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 160 India: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 161 India: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 162 India: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 163 India: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 164 South Korea: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 165 South Korea: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 166 South Korea: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 167 South Korea: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 168 South Korea: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 169 South Korea: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 170 South Korea: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 171 Australia: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 172 Australia: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 173 Australia: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 174 Australia: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 175 Australia: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 176 Australia: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 177 Australia: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 178 Rest of Asia-Pacific: Number of New Cancer Cases, By Country, 2022 Vs. 2030
Table 179 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 180 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 181 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 182 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 183 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 184 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 185 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 186 Latin America: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
Table 187 Latin America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 188 Latin America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 189 Latin America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 190 Latin America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 191 Latin America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 192 Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 193 Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 194 Brazil: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 195 Brazil: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 196 Brazil: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 197 Brazil: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 198 Brazil: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 199 Brazil: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 200 Brazil: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 201 Mexico: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 202 Mexico: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 203 Mexico: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 204 Mexico: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 205 Mexico: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 206 Mexico: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 207 Mexico: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 208 Rest of Latin America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 209 Rest of Latin America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 210 Rest of Latin America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 211 Rest of Latin America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 212 Rest of Latin America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 213 Rest of Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 214 Rest of Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 215 Middle East & Africa: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
Table 216 Middle East & Africa: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
Table 217 Middle East & Africa: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
Table 218 Middle East & Africa: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
Table 219 Middle East & Africa: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
Table 220 Middle East & Africa: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
Table 221 Middle East & Africa: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
Table 222 Recent Developments, By Company, 2021-2024

LIST OF FIGURES

Figure 1 Market Ecosystem
Figure 2 Research Process
Figure 3 Secondary Sources Referenced for This Study
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Sizing & Growth Forecast Approach
Figure 8 Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)
Figure 9 Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)
Figure 10 Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 11 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)
Figure 12 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
Figure 13 Global Minimal Residual Disease Testing Market, By Geography
Figure 14 Impact Analysis of Market Dynamics
Figure 15 USFDA Regulatory Pathways for IVD Products
Figure 16 Eu Regulatory Pathway - IVDR 2017/746
Figure 17 China: Medical Device Classification and Pre-Market Requirements for MRD Testing Instruments
Figure 18 Saudi Arabia: Medical Device - Marketing Authorization Process
Figure 19 Porter's Five Forces Analysis
Figure 20 Minimal Residual Disease Testing: Technology Evolution Roadmap
Figure 21 Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)
Figure 22 Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)
Figure 23 Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 24 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)
Figure 25 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
Figure 26 Global Minimal Residual Disease Testing Market, By Geography, 2024 Vs. 2031 (USD Million)
Figure 27 North America: Minimal Residual Disease Testing Market Snapshot
Figure 28 Europe: Minimal Residual Disease Testing Market Snapshot
Figure 29 U.K.: Number of New Cancer Cases, 2022-2040
Figure 30 France: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 31 Switzerland: Number of New Cancer Cases, 2022-2040
Figure 32 Netherlands: Number of New Cancer Cases, 2022-2040
Figure 33 Asia-Pacific: Minimal Residual Disease Testing Market Snapshot
Figure 34 South Korea: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 35 Latin America: Minimal Residual Disease Testing Market Snapshot
Figure 36 Mexico: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 37 Middle East & Africa: Number of New Cancer Cases, By Country, 2022 Vs. 2030
Figure 38 Key Growth Strategies Adopted By Leading Players, 2021-2024
Figure 39 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Technology
Figure 40 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Region
Figure 41 Competitive Dashboard: Minimal Residual Disease Testing Market
Figure 42 Global Minimal Residual Disease Testing Market Share Analysis, By Key Players (2023)
Figure 43 Natera Inc.: Financial Overview (2023)
Figure 44 Bio-Rad Laboratories, Inc.: Financial Overview (2023)
Figure 45 F. Hoffmann-La Roche Ltd.: Financial Overview (2023)
Figure 46 Adaptive Biotechnologies Corporation.: Financial Overview (2023)
Figure 47 Illumina Inc.: Financial Overview (2023)
Figure 48 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 49 Qiagen N.V.: Financial Overview (2023)
Figure 50 Danaher Corporation: Financial Overview (2023)
Figure 51 Twist Bioscience Corporation: Financial Overview (2023)
Figure 52 Sysmex Corporation: Financial Overview (2024)

Product Code: MRHC - 1041385

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow)-Global Forecast to 2031

According to a new market research report titled, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow)-Global Forecast to 2031' the minimal residual disease testing market is expected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024-2031.

Minimal Residual Disease (MRD) testing is crucial for cancer-affected patients. MRD tests provide early insights into whether a treated cancer patient is at risk of relapse or cancer recurrence. Early information helps physicians make treatment decisions depending on the cancer type and recurrence rates, which may lead to improved patient outcomes and better quality of life. Additionally, MRD testing is being increasingly used in clinical trials by pharmaceutical and biopharmaceutical companies focused on the development of cancer therapies. These are some of the major factors driving the adoption of MRD testing globally.

The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the increasing application of MRD in hematological malignancies, the high recurrence rates of some cancers, and increasing investments and funding for MRD testing. Moreover, emerging economies, the rising adoption of personalized treatments & targeted therapies in the field of oncology, and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities.

Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology

As researchers are able to identify the unique genetic profiles of tumors, MRD testing is gaining traction in personalized oncology medicine. By identifying residual cancer cells in a patient, physicians can make decisions about the intensity of the treatments or tailor treatments based on the individual's response to treatments. MRD testing goes hand in hand with personalized medicine to improve therapeutic efficacy and make patient management more precise.

The integration of MRD testing into clinical pathways supports the validation of targeted therapies. As new drugs are being developed to target specific genetic mutations, MRD testing can provide valuable insights into treatment effectiveness. For instance, in 2023, the U.S. FDA approved 16 personalized treatments for rare diseases, of which seven were for cancer. Combining targeted therapies and MRD testing can facilitate early intervention strategies, potentially preventing relapse and improving long-term outcomes for patients. Thus, the shift toward personalized treatments and targeted therapies in oncology is expected to generate growth opportunities for the players operating in the Minimal Residual Disease (MRD) testing market.

Minimal Residual Disease Testing Market: Future Outlook

The minimal residual disease testing market is segmented by Offering (Assays & Reagents, Instruments, and Software & Services), Technology (Flow Cytometry, Polymerase Chain Reaction [PCR], Next-generation Sequencing [NGS], and Other Technologies), Application (Blood Cancers [Lymphoma, Leukemia {Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, and Other Leukemias}, Multiple Myeloma, and Other Blood Cancers], and Solid Tumors), Sample Type (Blood, Bone Marrow, and Other Sample Types), Customer Type (Pharmaceutical & Biopharmaceutical Companies, Hospitals, Diagnostic Laboratories, and Academic & Research Organizations/Institutions), and Geography (North America [U.S. and Canada], Europe [Germany, France, U.K., Spain, Italy, Switzerland, Netherlands, and Rest of Europe], Asia-Pacific [China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific], Latin America [Brazil, Mexico, and Rest of Latin America], and the Middle East & Africa.

Among the offerings studied in this report, in 2024, the assays & reagents segment is expected to account for the largest share of 76.7% of the minimal residual disease testing market. The recurrent use of assays & reagents, increasing research & development in the field of oncology leading to the emergence of new MRD tests, market players' focus on introducing new assays for minimal residual disease testing, and the rising adoption of MRD testing in clinical trials, contribute to the substantial market share of this segment.

Among the technologies studied in this report, in 2024, the flow cytometry segment is expected to account for the largest share of 42.7% of the minimal residual disease testing market. This segment's significant market share is attributed to the technology's ability to provide real-time, quantitative data on the number and type of cancer cells in a sample, the widespread availability of flow cytometers, and the relatively lower costs of flow cytometry consumables compared to more advanced technologies such as Next-generation Sequencing (NGS).

Among the applications studied in this report, in 2024, the blood cancers segment is expected to account for the larger share of the minimal residual disease testing market. The segment's large share is attributed to the growing incidence of blood cancers, the advent of new diagnostic technologies, the rising focus on precision oncology, high investments in MRD testing for blood cancers, and the wide availability of MRD testing solutions for blood cancers.

Among the sample types studied in this report, in 2024, the blood segment is expected to account for the largest share of the minimal residual disease testing market. This segment holds a large market share due to the growing cancer incidence, the noninvasiveness of procedures used to obtain blood samples, and better patient compliance in the case of regular blood-based MRD monitoring.

Among the customer types studied in this report, in 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the minimal residual disease testing market. This segment's large market share is attributed to the high adoption of MRD testing in clinical trials for oncology therapies, high investments in oncology drug development and research, and supportive initiatives by regulatory authorities to promote MRD testing in drug trials.

Among the geographies studied in this report, in 2024, APAC is estimated to register the highest CAGR during the forecast period. Asia-Pacific is becoming an increasingly active market for healthcare product manufacturers and service providers due to improving healthcare infrastructure in the region. Asia-Pacific's growing population is the key factor driving the region's healthcare sector. This growth is attracting investments from private and public organizations in the development of MRD testing solutions. The rising incidence of cancer, improving healthcare infrastructure, the growing focus on personalized therapies, increasing cancer screening initiatives, and the availability of funding for cancer research are driving market growth in Asia-Pacific.

Some of the major players studied in this report are Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.).

Scope of the Report:

Minimal Residual Disease Testing Market Assessment-by Offering

Assays & Reagents

Instruments

Software & Services

Minimal Residual Disease Testing Market Assessment-by Technology

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-generation Sequencing (NGS)

Other Technologies

Minimal Residual Disease Testing Market Assessment-by Application

Blood Cancers

Lymphoma

Leukemia

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Other Leukemias

Multiple Myeloma

Other Blood Cancers

Solid Tumors

(Note: Other leukemias include chronic myeloid leukemia, B-cell prolymphocytic leukemia, and juvenile myelomonocytic leukemia.)

(Note: Other blood cancers include chronic myeloid leukemia, B-cell prolymphocytic leukemia, and juvenile myelomonocytic leukemia.)

Minimal Residual Disease Testing Market Assessment-by Sample Type

Blood

Bone Marrow

Other Sample Types

Minimal Residual Disease Testing Market Assessment-by Customer Type

Pharmaceutical & Biopharmaceutical Companies

Hospitals

Diagnostic Laboratories

Academic & Research Organizations/Institutions

Minimal Residual Disease Testing Market Assessment-by Geography

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Switzerland

Netherlands

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

1. Introduction

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Process
2.2. Data Collection & Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
2.3. Market Sizing & Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
  - 4.2.1.1. Growing Incidence of Cancer
  - 4.2.1.2. Increasing Investments & Funding for MRD Testing & Research
- 4.2.2. Restraints
  - 4.2.2.1. High Costs of Minimal Residual Disease Testing
- 4.2.3. Opportunities
  - 4.2.3.1. Rising Adoption of Personalized Treatments & Targeted Therapies In the Field of Oncology
  - 4.2.3.2. Growing Use of MRD Testing In Cases of Solid Tumors
- 4.2.4. Challenges
  - 4.2.4.1. Chances of False Positive/Negative Results
- 4.2.5. Trends
  - 4.2.5.1. Emergence of Digital PCR
  - 4.2.5.2. Use of Mass Spectrometry for MRD Testing
  - 4.2.5.3. Integration of Single-Cell Multiomics & Artificial Intelligence Into Minimal Residual Disease Testing
- 4.2.6. Factors Analysis
4.3. Regulatory Analysis
- 4.3.1. North America
  - 4.3.1.1. U.S.
  - 4.3.1.2. Canada
- 4.3.2. Europe
- 4.3.3. Asia-Pacific
  - 4.3.3.1. China
  - 4.3.3.2. Japan
  - 4.3.3.3. India
- 4.3.4. Latin America
- 4.3.5. Middle East
4.4. Porter's Five Forces Analysis
- 4.4.1. Bargaining Power of Buyers
- 4.4.2. Bargaining Power of Suppliers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Degree of Competition
4.5. Technology Evolution Roadmap

5. Minimal Residual Disease Testing Market Assessment- By Offering

5.1. Overview
5.2. Assays & Reagents
5.3. Instruments
5.4. Software & Services

6. Minimal Residual Disease Testing Market Assessment- By Technology

6.1. Overview
6.2. Flow Cytometry
6.3. Polymerase Chain Reaction
6.4. Next-Generation Sequencing
6.5. Other Technologies

7. Minimal Residual Disease Testing Market Assessment- By Application

7.1. Overview
7.2. Blood Cancers
- 7.2.1. Lymphoma
- 7.2.2. Leukemia
  - 7.2.2.1. Acute Lymphoblastic Leukemia (ALL)
  - 7.2.2.2. Chronic Lymphocytic Leukemia (CLL)
  - 7.2.2.3. Other Leukemias
- 7.2.3. Multiple Myeloma
- 7.2.4. Other Blood Cancers
7.3. Solid Tumors

8. Minimal Residual Disease Testing Market Assessment- By Sample Type

8.1. Overview
8.2. Blood
8.3. Bone Marrow
8.4. Other Sample Types

9. Minimal Residual Disease Testing Market Assessment- By Customer Type

9.1. Overview
9.2. Pharmaceutical & Biopharmaceutical Companies
9.3. Hospitals
9.4. Diagnostic Laboratories
9.5. Academic & Research Organizations/Institutions

10. Minimal Residual Disease Testing Market Assessment- By Geography

10.1. Overview
10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. Germany
- 10.3.2. U.K.
- 10.3.3. France
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Switzerland
- 10.3.7. Netherlands
- 10.3.8. Rest of Europe
10.4. Asia-Pacific
- 10.4.1. China
- 10.4.2. Japan
- 10.4.3. India
- 10.4.4. South Korea
- 10.4.5. Australia
- 10.4.6. Rest of Asia-Pacific
10.5. Latin America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of Latin America
10.6. Middle East & Africa

11. Competitive Landscape

11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
- 11.4.1. Industry Leaders
- 11.4.2. Market Differentiators
- 11.4.3. Vanguards
- 11.4.4. Emerging Companies
11.5. Market Share Analysis (2023)
- 11.5.1. Natera Inc. (U.S.)
- 11.5.2. Bio-Rad Laboratories, Inc. (U.S.)
- 11.5.3. F. Hoffmann-La Roche Ltd. (Switzerland)
- 11.5.4. Adaptive Biotechnologies Corporation (U.S.)

12. Company Profiles

12.1. Natera Inc.
12.2. Bio-Rad Laboratories, Inc.
12.3. F. Hoffmann-La Roche Ltd.
12.4. Adaptive Biotechnologies Corporation
12.5. Illumina, Inc.
12.6. Thermo Fisher Scientific, Inc.
12.7. Qiagen N.V.
12.8. Integrated DNA Technologies, Inc. (U.S.) (A Subsidiary of Danaher Corporation [U.S.])
12.9. Twist Bioscience Corporation
12.10. Sysmex Corporation
12.11. Invivoscribe, Inc.

13. Appendix

13.1. Available Customization
13.2. Related Reports

微小残存病変検査市場規模、シェア、予測、動向分析：提供別、技術別（PCR、フローサイトメトリー、NGS）、用途別（リンパ腫、白血病、多発性骨髄腫、固形腫瘍）、検体タイプ別（血液、骨髄） - 2031年までの世界予測

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) - Global Forecast to 2031

目次

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章市場洞察

第5章微小残存病変検査市場の評価-提供別

第6章微小残存病変検査市場の評価-技術別

第7章微小残存病変検査市場の評価-用途別

第8章微小残存病変検査市場の評価-検体タイプ別

第9章微小残存病変検査市場の評価-顧客タイプ別

第10章微小残存病変検査市場の評価-地域別

第11章競合情勢

第12章企業プロファイル

第13章付録

LIST OF TABLES

LIST OF FIGURES

Scope of the Report:

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

5. Minimal Residual Disease Testing Market Assessment- By Offering

6. Minimal Residual Disease Testing Market Assessment- By Technology

7. Minimal Residual Disease Testing Market Assessment- By Application

8. Minimal Residual Disease Testing Market Assessment- By Sample Type

9. Minimal Residual Disease Testing Market Assessment- By Customer Type

10. Minimal Residual Disease Testing Market Assessment- By Geography

11. Competitive Landscape

12. Company Profiles

13. Appendix

微小残存病変検査市場規模、シェア、予測、動向分析：提供別、技術別（PCR、フローサイトメトリー、NGS）、用途別（リンパ腫、白血病、多発性骨髄腫、 固形腫瘍）、検体タイプ別（血液、骨髄） - 2031年までの世界予測

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) - Global Forecast to 2031

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

第5章 微小残存病変検査市場の評価-提供別

第6章 微小残存病変検査市場の評価-技術別

第7章 微小残存病変検査市場の評価-用途別

第8章 微小残存病変検査市場の評価-検体タイプ別

第9章 微小残存病変検査市場の評価-顧客タイプ別

第10章 微小残存病変検査市場の評価-地域別

第11章 競合情勢

第12章 企業プロファイル

第13章 付録

LIST OF TABLES

LIST OF FIGURES

Scope of the Report:

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

5. Minimal Residual Disease Testing Market Assessment- By Offering

6. Minimal Residual Disease Testing Market Assessment- By Technology

7. Minimal Residual Disease Testing Market Assessment- By Application

8. Minimal Residual Disease Testing Market Assessment- By Sample Type

9. Minimal Residual Disease Testing Market Assessment- By Customer Type

10. Minimal Residual Disease Testing Market Assessment- By Geography

11. Competitive Landscape

12. Company Profiles

13. Appendix

微小残存病変検査市場規模、シェア、予測、動向分析：提供別、技術別（PCR、フローサイトメトリー、NGS）、用途別（リンパ腫、白血病、多発性骨髄腫、固形腫瘍）、検体タイプ別（血液、骨髄） - 2031年までの世界予測

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章市場洞察

第5章微小残存病変検査市場の評価-提供別

第6章微小残存病変検査市場の評価-技術別

第7章微小残存病変検査市場の評価-用途別

第8章微小残存病変検査市場の評価-検体タイプ別

第9章微小残存病変検査市場の評価-顧客タイプ別

第10章微小残存病変検査市場の評価-地域別

第11章競合情勢

第12章企業プロファイル

第13章付録